Literature DB >> 24371025

Arterial spin-labeling evaluation of cerebrovascular reactivity to acetazolamide in healthy subjects.

Y Inoue1, Y Tanaka2, H Hata2, T Hara3.   

Abstract

BACKGROUND AND
PURPOSE: Arterial spin-labeling MR imaging permits safe, repeated CBF measurement. We investigated the potential and technical factors of arterial spin-labeling imaging in assessing cerebrovascular reactivity to acetazolamide.
MATERIALS AND METHODS: The regional CBF was measured in 8 healthy volunteers by use of a 3D pseudocontinuous arterial spin-labeling sequence. Arterial spin labeling imaging was performed at rest and every 2 minutes after intravenous acetazolamide injection. To evaluate repeatability, regional CBF measurements were repeated without acetazolamide within an imaging session and on a separate day. Additionally, arterial spin-labeling imaging was performed at rest and after acetazolamide injection with different postlabeling delays, and regional cerebrovascular reactivity was calculated.
RESULTS: The regional CBF started to increase immediately after acetazolamide injection and peaked at approximately 10 minutes, followed by a slow decrease. Favorable intrasession repeatability was demonstrated, especially when scanner tuning was omitted between scans. Rest regional CBF was slightly lower with a postlabeling delay of 2525 ms than with a postlabeling delay of 1525 ms, and the postlabeling delay-dependent difference was more evident for regional CBF after acetazolamide injection and regional cerebrovascular reactivity.
CONCLUSIONS: Arterial spin-labeling imaging allows evaluation of the distribution, magnitude, and time course of cerebrovascular response to acetazolamide. The influence of the postlabeling delay on the estimated cerebrovascular reactivity should be noted.
© 2014 by American Journal of Neuroradiology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24371025      PMCID: PMC7965130          DOI: 10.3174/ajnr.A3815

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  30 in total

1.  Noninvasive magnetic resonance imaging evaluation of cerebral blood flow with acetazolamide challenge in patients with cerebrovascular stenosis.

Authors:  J A Detre; O B Samuels; D C Alsop; J B Gonzalez-At; S E Kasner; E C Raps
Journal:  J Magn Reson Imaging       Date:  1999-11       Impact factor: 4.813

Review 2.  Non-invasive measurement of perfusion: a critical review of arterial spin labelling techniques.

Authors:  E T Petersen; I Zimine; Y-C L Ho; X Golay
Journal:  Br J Radiol       Date:  2006-08       Impact factor: 3.039

3.  Assessment of arterial arrival times derived from multiple inversion time pulsed arterial spin labeling MRI.

Authors:  Bradley J MacIntosh; Nicola Filippini; Michael A Chappell; Mark W Woolrich; Clare E Mackay; Peter Jezzard
Journal:  Magn Reson Med       Date:  2010-03       Impact factor: 4.668

4.  Volumetric cerebral perfusion imaging in healthy adults: regional distribution, laterality, and repeatability of pulsed continuous arterial spin labeling (PCASL).

Authors:  Adolf Pfefferbaum; Sandra Chanraud; Anne-Lise Pitel; Ajit Shankaranarayanan; David C Alsop; Torsten Rohlfing; Edith V Sullivan
Journal:  Psychiatry Res       Date:  2010-05-20       Impact factor: 3.222

Review 5.  Positron emission tomography and its application to the study of cerebrovascular disease in man.

Authors:  W J Powers; M E Raichle
Journal:  Stroke       Date:  1985 May-Jun       Impact factor: 7.914

6.  Symptomatic carotid artery stenosis: impairment of cerebral autoregulation measured at the brain tissue level with arterial spin-labeling MR imaging.

Authors:  Reinoud P H Bokkers; Matthias J P van Osch; H Bart van der Worp; Gert J de Borst; Willem P T M Mali; Jeroen Hendrikse
Journal:  Radiology       Date:  2010-07       Impact factor: 11.105

7.  Usefulness of a three-dimensional stereotaxic ROI template on anatomically standardised 99mTc-ECD SPET.

Authors:  Ryo Takeuchi; Yoshiharu Yonekura; Hiroshi Matsuda; Junji Konishi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-03       Impact factor: 9.236

8.  Effects of acetazolamide on cerebral blood flow, blood volume, and oxygen metabolism: a positron emission tomography study with healthy volunteers.

Authors:  H Okazawa; H Yamauchi; K Sugimoto; H Toyoda; Y Kishibe; M Takahashi
Journal:  J Cereb Blood Flow Metab       Date:  2001-12       Impact factor: 6.200

Review 9.  Arterial spin-labeled MR perfusion imaging: clinical applications.

Authors:  Jeffrey M Pollock; Huan Tan; Robert A Kraft; Christopher T Whitlow; Jonathan H Burdette; Joseph A Maldjian
Journal:  Magn Reson Imaging Clin N Am       Date:  2009-05       Impact factor: 2.266

10.  Acute effects of acetazolamide on cerebral blood flow in man.

Authors:  A Hauge; G Nicolaysen; M Thoresen
Journal:  Acta Physiol Scand       Date:  1983-02
View more
  9 in total

1.  Cerebral blood flow territory instability in patients with atherosclerotic intracranial stenosis.

Authors:  Daniel F Arteaga; Megan K Strother; Carlos C Faraco; L Taylor Davis; Allison O Scott; Manus J Donahue
Journal:  J Magn Reson Imaging       Date:  2019-04-02       Impact factor: 4.813

2.  Higher cardiovascular fitness level is associated with lower cerebrovascular reactivity and perfusion in healthy older adults.

Authors:  Brittany Intzandt; Dalia Sabra; Catherine Foster; Laurence Desjardins-Crépeau; Richard D Hoge; Christopher J Steele; Louis Bherer; Claudine J Gauthier
Journal:  J Cereb Blood Flow Metab       Date:  2019-07-25       Impact factor: 6.200

3.  Imaging of cerebrovascular reserve and oxygenation in Moyamoya disease.

Authors:  Wendy W Ni; Thomas Christen; Jarrett Rosenberg; Zungho Zun; Michael E Moseley; Greg Zaharchuk
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

4.  High Intravascular Signal Arterial Transit Time Artifacts Have Negligible Effects on Cerebral Blood Flow and Cerebrovascular Reserve Capacity Measurement Using Single Postlabel Delay Arterial Spin-Labeling in Patients with Moyamoya Disease.

Authors:  M Fahlström; A Lewén; P Enblad; E-M Larsson; J Wikström
Journal:  AJNR Am J Neuroradiol       Date:  2020-02-27       Impact factor: 3.825

5.  Cerebral collateral therapeutics in acute ischemic stroke: A randomized preclinical trial of four modulation strategies.

Authors:  Simone Beretta; Alessandro Versace; Davide Carone; Matteo Riva; Valentina Dell'Era; Elisa Cuccione; Ruiyao Cai; Laura Monza; Silvia Pirovano; Giada Padovano; Fabio Stiro; Luca Presotto; Giovanni Paternò; Emanuela Rossi; Carlo Giussani; Erik P Sganzerla; Carlo Ferrarese
Journal:  J Cereb Blood Flow Metab       Date:  2017-01-23       Impact factor: 6.200

6.  Age‑ and brain region‑associated alterations of cerebral blood flow in early Alzheimer's disease assessed in AβPPSWE/PS1ΔE9 transgenic mice using arterial spin labeling.

Authors:  Yapei Guo; Xueyuan Li; Min Zhang; Ningning Chen; Shitao Wu; Jianfeng Lei; Zhanjing Wang; Renzhi Wang; Jianping Wang; Hengfang Liu
Journal:  Mol Med Rep       Date:  2019-02-12       Impact factor: 2.952

7.  Cerebrovascular Reactivity Measurement Using Magnetic Resonance Imaging: A Systematic Review.

Authors:  Emilie Sleight; Michael S Stringer; Ian Marshall; Joanna M Wardlaw; Michael J Thrippleton
Journal:  Front Physiol       Date:  2021-02-25       Impact factor: 4.566

8.  Cerebrovascular Reservoir and Arterial Transit Time Changes Assessed by Acetazolamide-Challenged Multi-Phase Arterial Spin Labeling Perfusion MRI in Chronic Cerebrovascular Steno-Occlusive Disease.

Authors:  Inpyeong Hwang; Chul-Ho Sohn; Keun-Hwa Jung; Eung Koo Yeon; Ji Ye Lee; Roh-Eul Yoo; Koung Mi Kang; Tae Jin Yun; Seung Hong Choi; Ji-Hoon Kim
Journal:  Taehan Yongsang Uihakhoe Chi       Date:  2021-01-29

9.  Acetazolamide-augmented dynamic BOLD (aczBOLD) imaging for assessing cerebrovascular reactivity in chronic steno-occlusive disease of the anterior circulation: An initial experience.

Authors:  Junjie Wu; Seena Dehkharghani; Fadi Nahab; Deqiang Qiu
Journal:  Neuroimage Clin       Date:  2016-11-17       Impact factor: 4.881

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.